Allogeneic BMT remains the most effective curative strategy for patients with high-risk AML or adverse cytogenetics and molecular abnormalities such as BCR::ABL1 and, in fact, may provide superior survival outcomes compared to chemotherapy alone [7]. The gene discussed is ABL1; the disease is acute myeloid leukemia.